Elsy Boglioli joined Cellectis in December 2017 as Executive Vice President, Strategy and Corporate Development. Prior to joining Cellectis, Elsy worked at the Boston Consulting Group (BCG) where she served as Partner and Managing Director, and leader of BCG’s biotech-focused business in Europe. Ms. Boglioli has far-reaching expertise within the pharma and medtech industries, focusing on everything from corporate strategy and M&A to research. At BCG, she was also a member of the global biopharma leadership team and global strategy practice management team and served as regional head of the strategy practice for Europe. Ms. Boglioli graduated from Ecole Polytechnique in Paris, France and holds a master’s degree in economy and management from Pompeu Fabra University in Barcelona, Spain.
Alex Koglin, Ph.D. is a co-founder of NTxBio, a Santa Fe-based start-up developing a platform technology to synthesize novel biomolecules. Dr. Koglin came to New Mexico in 2009 as J Robert Oppenheimer Fellow at the Los Alamos National Laboratory where he focused his work on enzyme clusters in natural product biosynthesis and the identification of novel chemical cores of bioactive compounds. He completed his Ph.D. in biophysics at Goethe University, Frankfurt/Main, Germany in 2006 where he determined protein structures and elucidated slow-motion allosteric dynamics of proteins involved in natural product biosynthesis and continued his research as a Human Frontier Science Program long-term Research Scholar at Harvard Medical School.
Mr. Hamilton attended DePauw University, Greencastle, Indiana. Upon completing the BA requirements in 1964 as a Phi Beta Kappa, Bud went on to get his MBA at Harvard. Upon graduation from HBS in 1966, he joined the Procter & Gamble Company where he was employed for the next 37 years in various executive positions in Sales, Marketing, General Management. In the latter years of his career Bud served as President Eurocos (P&G Fine Fragrance Subsidiary), Vice President Customer Marketing North America, Vice President Customer Business Development North America, Vice President Global Innovation.
Mr. Wagner has been a co-founder, board member and held executive management positions in two venture backed spinal implant companies including Spinal Concepts (1996) and Flexuspine (2005). At Spinal Concepts, he and his partners raised over $45 million in venture capital leading the company to profitability in less than six years on sales exceeding $10 million/month and growing at 70% CAGR. He left Spinal Concepts following the sale of the company to Abbott Labs for $170 million in 2003. His proven record for innovation and leadership has continued at Flexuspine with the development and clinical investigation of the world’s first spinal segmental reconstruction device. He has over 70 patents on devices ranging from spinal implants to cardiovascular atherectomy devices and currently serves on the board of directors at Flexuspine. He continues to serve as a business consultant and advisor to other medical device startups and investor groups.
Dr. Robert Wassman
Dr. Robert Wassman, MD, Medical Geneticist is as Chief Medical Adviser at Lineagen, Inc. Dr. Wassman has more than 30 years of experience in executive roles. He was a Co-Founder of Good Start Genetics and served as its Chief Medical Officer. He served as President and Chief Medical Officer of Celula, Inc. He served as the Chief Medical Officer of Rosetta Genomics, Ltd. from October 2012 to September 18, 2015. Prior to joining Lineagen, Dr. Wassman served in various positions focused on advancing the translation and delivery of cutting-edge diagnostic technology into clinical service.